Method
We conducted a study on 50 patients who underwent retropubic radical prostatectomy following neoadjuvant therapy for clinical stage T1c, T2, and T3a prostate cancer.
Serum PSA (Tosoh AIA-PACK PA, Tosoh) levels before and after initiation of neoadjuvant therapy were determined monthly. The last PSA levels before the patient underwent radical prostatectomy were de®ned as PSA nadir.
We analysed the predictive value of PSA nadir after neoadjuvant therapy and other clinical factors in order to determine the most important predictor of organ con®ne-ment using logistic regression analysis.
Results
Of the 50 patients, 27 had organ-con®ned disease. Clinical stage (P 0.049), baseline PSA (P 0.024), PSA nadir (P`0.0001) and PSAD (P 0.011) correlated signi®cantly with organ con®nement. Multivariate logistic regression analysis revealed that PSA nadir was the only independent predictor of organ con®nement (P 0.021). Stepwise logistic regression analysis revealed that PSA nadir level alone was the best predictor of organ-con®nement status (P 0.011). PSA nadir correlated signi®cantly with the incidence of organ-con®ned disease in patients with clinical stage T2 or T3a. PSA nadir also correlated signi®cantly with the incidence of organ-con®ned disease in patients with baseline PSA 10.1 ng/ml and well or moderately differentiated tumours. There was no signi®-cant correlation between PSA nadir and the incidence of organ-con®ned disease in patients with clinical stage T1c, PSA 10.0 ng/ml or poorly differentiated tumours.
Conclusion
PSA nadir after neoadjuvant therapy was the strongest predictor of organ-con®nement among clinical predictors including clinical stage, baseline PSA and PSAD. PSA nadir level may not help predict non-organ-con®ned disease in patients with clinical stage T1c, PSA 10.0 ng/ml or poorly differentiated tumours.
However, the predictive value of serum PSA nadir should be validated not only by pathological outcome, but also by progression-free survival based on follow-up PSA levels. The duration of neoadjuvant therapy and surgical indication by PSA monitoring has still to be determined in larger population-based studies.
